1534 ET - Eli Lilly's weight-loss pill slightly missed the company's efficacy expectations, but shares slid more than they should've, say UBS analysts. The pill led to 12.4% weight loss, which suggests it's still a viable drug. Consumers who want an oral GPL-1 drug may be willing to sacrifice some efficacy to avoid needles. The pill version will also cater to those looking to buy in cash, who value convenience over maximum efficacy, the analysts say. But the lower efficacy could lead Eli Lilly to offer the pill at a discount, which would hurt its potential boost to the company's earnings. (nicholas.miller@wsj.com)
(END) Dow Jones Newswires
August 08, 2025 15:34 ET (19:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.